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Abstract
Carbonate in its various forms is an important component in blood and the cytosol. Since, under conditions that simulate therapy,
carbonate reacts with cisplatin to form carbonato complexes, one of which is taken up and/or modified by the cell [C.R. Centerwall, J.
Goodisman, D.J. Kerwood, J. Am. Chem. Soc., 127 (2005) 12768–12769], cisplatin-carbonato complexes may be important in the mech-
anism of action of cisplatin. In this report we study the binding of cisplatin to pBR322 DNA in two different buffers, using gel electro-
phoresis. In 23.8 mM HEPES, N-(2-hydroxyethyl)-piperazine-N 0-2-ethanesulfonic acid, 5 mM NaCl, pH 7.4 buffer, cisplatin produces
aquated species, which react with DNA to unwind supercoiled Form I DNA, increasing its mobility, and reducing the binding of ethi-
dium to DNA. This behavior is consistent with the formation of the well-known intrastrand crosslink on DNA. In 23.8 mM carbonate
buffer, 5 mM NaCl, pH 7.4, cisplatin forms carbonato species that produce DNA-adducts which do not significantly change supercoiling
but enhance binding of ethidium to DNA. This behavior is consistent with the formation of a monofunctional cisplatin adduct on DNA.
These results show that aquated cisplatin and carbonato complexes of cisplatin produce different types of lesions on DNA and they
underscore the importance of carrying out binding studies with cisplatin and DNA using conditions that approximate those found in
the cell.
 2006 Elsevier Inc. All rights reserved.
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1. Introduction
Cisplatin, cis-diamminedichloroplatinum(II), 1, Scheme
1, is one of the most successful drugs currently in use for
treating cancer [1]. In the clinical formulation of cisplatin
called Platinol, the hydrolysis of 1 is suppressed by the
addition of 154 mM NaCl but some hydrolysis (15%) to
cis-[Pt(NH3)2(H2O)(Cl)]
+, 2, still occurs [2,3] (Scheme 1).
As the drug enters the blood, where the chloride concentra-
tion is 105 mM, additional hydrolysis of 1 to 2 can take
place. Since the pKa for the deprotonation of the mono-
aquo form, 2, to produce the corresponding hydroxo spe-
cies, cis-[Pt(NH3)2(OH)(Cl)], 3, is 6.56 [4], both 2 and 3
are present at physiological pH (pH 7.4). Compounds 1–
3 may react with components in the blood or they may
enter the cytosol and react with components inside the cell
to elicit their biological effects.
It is widely accepted that the target for platinum drugs is
nuclear DNA [1]. However, DNA binding studies involv-
ing cisplatin and its analogs have usually been done using
conditions, which do not simulate those found in blood
or the cytosol. For example, earlier we studied the binding
of cisplatin and cis-Pt((CH3)2CHNH2)2Cl2 to PM2 DNA
in the buffer tris(hydroxymethyl)aminomethane-nitrate
(TRIS-NO3) [5]. Nitrate ion is a poor ligand for binding
to metal ions [6] and, because the primary amine of TRIS
is largely protonated at physiological pH, it has limited
availability for reaction with Pt+2 [7]. In this buffer, the
platinum drugs formed aquated species that bound to
and unwound closed circular PM2 DNA [5].
In contrast, carbonate, which is a good nucleophile for
metal ions [8,9], is a major component of blood, yet it is
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rarely present in DNA binding studies involving cisplatin
and its analogues. The total concentration of all carbonate
forms in blood (carbonate ion, bicarbonate, carbonic acid,
and dissolved carbon dioxide), which are in equilibrium
with each other, is 24 mM. Although the intra- and
extra-cellular cellular concentrations of carbonate are sim-
ilar, stress applied to the cell can cause the former to be
much greater than 24 mM [10].
Extensive work by Harris, van Eldik, and others
[8,11,12] has shown that carbonate in its various forms
can react with metal ions to form carbonato complexes.
This can occur by attack of carbonate ion with the subse-
quent displacement of a metal-bound ligand (usually
water), or by the reaction of dissolved carbon dioxide gas
with a hydroxo species which has a metal-bound hydroxide
ligand. Since the latter reaction does not involve a metal-
ligand bond-breaking step, it occurs on the millisecond
time frame, allowing a hydroxo complex to rapidly convert
to its corresponding carbonato species. Depending on the
pH of the medium and the pKb for the protonation of
the bound carbonato ligand, the complex can remain as a
carbonato species or it can protonate to its bicarbonato
form. In most cases the bicarbonato complex rapidly
decarboxylates to its hydroxo form (loses CO2) but some
stable bicarbonato complexes are also known [8,11,13].
These transformations have been implicated in the mecha-
nism of action of human carbonic anhydrase, which cata-
lyzes the reversible hydration of CO2 [8].
Earlier we used 1H, 15N HSQC NMR and other tech-
niques to show that cisplatin reacts with carbonate in car-
bonate buffer to produce the carbonato complexes 4 and 5,
Scheme 1 [14]. If Jurkat cells are present in the medium, 4 is
readily taken up and/or modified by the cells [15], suggest-
ing that it may be the platinum species responsible for the
biological effects of cisplatin. In this report we study the
binding of cisplatin to purified closed circular pBR322
DNA using agarose gel electrophoresis with two different
buffers. One buffer contains 23.8 mM HEPES, N-(2-
hydroxyethyl)-piperazine-N 0-2-ethanesulfonic acid, which
interacts only weakly with platinum. This buffer allows cis-
platin aquo species to form and interact with DNA. The
second buffer, which contains 23.8 mM carbonate (the
approximate concentration of carbonate in the cytosol),
interacts with cisplatin to form carbonato species as shown
in Scheme 1 [14]. Both buffers contained 5 mM NaCl, the
approximate chloride ion concentration in the cytosol.
We found that, as expected, cisplatin binding to DNA in
HEPES buffer significantly changes the supercoiling (writh-
ing) of Form I DNA and decreases ethidium binding to
DNA. This behavior is consistent with the formation of
the aquated species 2 (3), which reacts with DNA to form
an intrastrand crosslink. However, in carbonate buffer
which allows the formation of cisplatin-carbonato species,
cisplatin binding to DNA causes little or no change in the
amount of supercoiling but it significantly increases ethi-
dium binding to DNA. This behavior is consistent with
the formation of a monofunctional cisplatin adduct on
DNA. Since cisplatin carbonato complexes can form under
physiological conditions and since they may enter the
cell, understanding the interaction of platinum carbonato
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Scheme 1. Reaction products of cisplatin in HEPES and carbonate buffers and type of adducts formed with pBR322 DNA.
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species with DNA should be important in understanding
the molecular mechanism of action of cisplatin.
2. Materials and methods
The DNA binding studies were done in a total volume
of 20 ll containing 5.0 mM NaCl and 19.2 lM (bp)
pBR322 DNA (Sigma–Aldrich), and either 23.8 mM
HEPES, N-(2-hydroxyethyl)-piperazine-N 0-2-ethanesulf-
onic acid, (pH 7.4) or 23.8 mM carbonate (NaHCO3,
Sigma–Aldrich, St. Louis, MO) (pH 7.4). The stock solu-
tion of cisplatin (Sigma–Aldrich) (3.0 mM) in aqueous
150 mM NaCl was diluted immediately before use to give
working solutions containing 10 mM NaCl and cisplatin
concentrations in the range 10–200 lM. Appropriate vol-
umes of the working solutions and 10 mM NaCl were
added to solutions containing the buffer and DNA to give
the final concentrations given above and values of r,
r = [1]/[DNA-bp], given in the captions to figures. The
samples were incubated at 37 C for 24 h in sealed Eppen-
dorf tubes after which time 8 ll of solution were removed
from the reaction tube and 1 ll of a solution containing
50% glycerol, 0.25% bromophenol blue and 0.25% xylene
cyanol was added. A 8 ll volume of each solution contain-
ing the loading the glycerol and dyes was loaded in the
wells of a 1% agarose gel and electrophoresis was carried
out for a period of 4 h, at 75 V. After electrophoresis,
the gel was immersed in 1 l of deionized water containing
100 ll of a 10 mg/ml solution of ethidium bromide for
15 min to stain DNA and then soaked in water alone for
15 min to de-stain the background of the gel. A digital
image of the stained gel was captured using a Kodak Gel
Logic 100 equipped with Fisher Biotech IT-88A transillu-
minator and band intensities (in arbitrary units) were deter-
mined using Kodak software and SigmaScan (v. 4.0). All
captured images were below saturation, in the linear
response range of the image capture system, and indepen-
dent of the orientation of the gel on the transilluminator.
3. Results and discussion
Figs. 1–3 are the results of cisplatin binding to pBR322
DNA in two different buffers, 23.8 mM carbonate pH 7.4
(left side of gels) and HEPES buffer, pH 7.4 (right side of
gels). The fastest migrating form of the DNA in the gel is
the closed circular form, Form I, while the slower moving
band is the nicked circular form, Form II [16–18]. While
Forms I and II DNA in carbonate buffer exhibit only small
changes in mobility with changes in r, the staining intensity
of the DNA in the gel clearly increases as r increases. Fig. 4
Fig. 1. Ethidium stained agarose gel of pBR322 DNA (19.2 lM bp) in the presence of cisplatin. 23.8 mM HEPES buffer, pH 7.4, lanes 1–7; 23.8 mM
carbonate buffer, pH 7.4, lanes 8–15. The lane numbers and value of r:1, 9, 0.078; 2, 10, 0.091; 3, 11, 0.104; 4, 12, 0.117; 5, 13, 0.130; 6, 14, 0.143; 7, 15,
0.156; 8, 0 (control). r = [cisplatin]/[DNA-bp].
Fig. 2. Ethidium stained agarose gel. See Fig. 1 caption for more details. The lane numbers and value of r:1, 9, 0.26; 2, 10, 0.52; 3, 11, 0.78; 4, 12, 1.04; 5,
13, 1.30; 6, 14, 1.56; 7, 15, 1.82; 8, 0 (control).
Fig. 3. Ethidium stained agarose gel. See Fig. 1 caption for more details. The lane numbers and value of r:1, 9, 1.56; 2, 10, 1.82; 3, 11, 2.08; 4, 12, 2.34; 5,
13, 2.60; 6, 14, 2.86; 7, 15, 3.13; 8, 0 (control).
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shows band intensities for Forms I and II (in arbitrary
units), from the gels shown in Figs. 1–3, plotted as func-
tions of r, with linear least-square fits to the points.
Fig. 4a corresponds to r 6 0.156 (gel shown in Fig. 1)
and Fig. 4b, which combines results from the gels shown
in Figs. 2 and 3, corresponds to a 20-fold greater range
of r.
The slope of each linear fit is divided by the y-intercept
to give the relative slope. For Form I pBR322 DNA, the
relative slope is 2.1 in the upper panel and 0.37 in the lower.
For Form II, the relative slope is 3.8 in the upper panel and
1.7 in the lower. Thus the increase of band intensity with
drug concentration in carbonate buffer is faster for lower
concentrations of cisplatin, and slower for higher drug con-
centrations. The increase in band intensity with increased
cisplatin concentration implies that cisplatin binds to
Forms I and II of pBR322 DNA in carbonate buffer.
(However, the binding hardly affects DNA mobility, as
shown below.) This conclusion, that cisplatin binds to
DNA in carbonate solution, was also reached by Fichtin-
ger-Schepman, et al. [19] who studied the binding of cis-
platin to salmon sperm DNA (r  0.06) in the presence
of 20 mM NaCl, NaHCO3, and NH4HCO3. They used
atomic absorption spectroscopy to show that, when com-
pared to an incubation medium which has no salt or buffer,
all three salts allowed about the same amount of platinum
to bind to DNA (30% of the amount in a salt-free med-
ium). Assuming that the intensity is a linear function of
the number of cisplatin adducts on DNA, the intensity data
in Fig. 4 can be fitted reasonably well by a Langmuir iso-
therm, which is appropriate for ligand binding to a multi-
ple-site DNA lattice [20].
As expected, cisplatin binds to and unwinds closed cir-
cular Form I DNA in HEPES buffer, Figs. 1–3, right side
of gels. Since cisplatin binding is believed to produce an
intrastrand crosslink on DNA which reduces the twist
angle at the site [21], the lesion causes the DNA form to
reduce its writhing which is manifested by a change in
the mobility of the form (measured by the distance traveled
in the gel). Since Form I pBR322 DNA is negatively super-
coiled, low values of r make the writhing less negative, i.e.,
closer to zero, which should open up the structure. The
effect of this can be seen in Fig. 1, for r 6 0.156, which
shows that the mobility of Form I decreases as r increases.
At higher values of r, Figs. 2 and 3, platinum binding to
Form I increases the writhing to zero and then changes
its sign (positive supercoiling), so that increased binding
should increase the mobility of this form in the gel, as
observed. Also evident from Figs. 1–3 is that in HEPES
buffer the mobility of the nicked circular Form II DNA,
which has no supercoiling, increases at all values of r.
Although this effect was previously observed [17], its struc-
tural origin is unknown. Cisplatin binding to DNA in
HEPES causes a decrease in the staining intensity of the
DNA forms which, at large r, makes DNA difficult to
detect in the gel, Fig. 3. Formation of the intrastrand cross-
link is known to reduce ethidium binding to DNA [16–
18,22]
In Fig. 5 we show the mobilities as functions of r for
Forms I and II pBR322 DNA in carbonate buffer. The
lines are least-square linear fits. For r 6 0.156, the mobili-
ties are not changed much by cisplatin in carbonate buffer,
indicating that binding does not greatly change the degree
of supercoiling of Form I DNA and it does not change the
structure of Form II. The slopes of both lines in Fig. 5a are
small and negative, 17 ± 8 and 8 ± 7 for Forms I and II
respectively (compare 764 ± 93 and 305 ± 34 for Forms I
and II in HEPES). In Fig. 5b, however, where r 6 3.2, the
line for Form I DNA has a small negative slope
(2.4 ± 0.4) but the line for Form II DNA has a small
positive slope (+2.2 ± 0.3). The negative slopes for Form
I indicate a decrease in supercoiling for small r; since the
supercoiling (writhing) is originally negative, it is becoming
less negative.
As we earlier showed [14], cisplatin reacts with carbon-
ate to form carbonato complexes, one of which, 4, is taken
up and/or modified by Jurkat cells in culture. In carbonate
buffer, a second carbonato complex, cis-[Pt(NH3)2-
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Fig. 4. Gel spot intensities (in arbitrary units) of Forms I and II in
carbonate increase with r. (a) Top, squares, closed circular Form I
pBR322 DNA; bottom, circles, nicked circular Form II DNA for gel
shown in Fig. 1. (b) Top, squares, Form I DNA; bottom, circles, Form II
DNA for gels shown in Figs. 2 and 3. Lines are linear least-square fits.
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(CO3)2]
2, 5, forms and one or both of these species could
be interacting with pBR322 DNA in the gel studies. In
addition to carbonate, the buffer medium contains a small
amount of chloride ion (5 mM) to simulate the concentra-
tion of this ion in the cytosol. Since the carbonato com-
plexes could be partially protonated at pH 7.4, to give
their bicarbonato and/or hydroxo forms [8], the equilibria
defining the interaction of 4 and/or 5 with DNA are com-
plex. However, it is possible that the DNA adduct formed
in carbonate buffer retains a platinum-bound carbonato
ligand, which is a poorer leaving ligand than, for example,
chloride. The presence of an anionic carbonato ligand at
the site of the platinum lesion could allow additional ethi-
dium, which is a cation, to associate with DNA thus
enhancing fluorescence. In HEPES buffer, and in other
media having poor metal binding ligands, cisplatin aquates
to form 2 (3) which subsequently attacks DNA with the
loss of bound water [23,24]. This initially formed mono-
functional adduct ultimately losses the chloro ligand to
form a bifunctional intrastrand crosslink, which changes
the degree of supercoiling. Reduced fluorescence in HEPES
could be caused by the ability of cationic platinum adducts
to reduced binding of cationic ethidium near the lesion
and/or to platinum-induced structural changes in DNA
which hinder intercalation of ethidium [18,22].
The small changes observed in the mobility for DNA
exposed to cisplatin in carbonate buffer are similar to those
recently observed for a potentially new antitumor drug, cis-
K[Ru(eddp)Cl2], reported by González-Vı́lchez and
coworkers [25]. The authors attributed the small changes
in mobility at low values of r to monofunctional binding
of the ruthenium complex to pBR322 DNA. Small changes
in mobility of supercoiled DNA also occur for a platinum
complex that forms a monofunctional adduct with guanine
residues on DNA [26] as well as with sterically hindered
Pt+2 and Pd+2 complexes containing mepirizole as the
non-leaving ligand [27]. Thus the lack of DNA unwinding
by cisplatin in carbonate buffer strongly suggests that the
drug is binding to DNA in a monofunctional manner.
Clearly, the composition of the medium significantly
influences the outcome of the binding experiment and addi-
tional work will be necessary to determine the structural
relationship between the lesion formed in carbonate buffer
to that produced when carbonate is absent from the med-
ium. As was earlier pointed out, carbonate in its various
forms is ubiquitous in biological systems and it readily
reacts with metal ions to form carbonato complexes
[8,11–13]. In particular, carbonate can react with cisplatin
to form carbonato species and, as we have recently shown
[28], it can open the bidentate dicarboxylate chelate ring of
the related platinum drug carboplatin. We hope that this
report will stimulate new interest on the potential role of
carbonate in the molecular mechanism of action of plati-
num-based anticancer drugs.
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